Basic Research - Cancer(구연) Oral Session1 / Basic Research - Cancer (Ⅰ) (O-009) Rm.201 10월 30일(수) 13:00-14:00 골수 조혈 줄기 세포에서 유래 된 수상 세포를 이용한 면역 요법의 전립선 암의 TRAMP-C1 동족 마우스 모델에서의 효과 울산대학교 의과대학, 서울아산병원 비뇨기과 임범진¹, 김윤림¹·²,김봉민¹·이현아³,김현수³,유달산¹,정인갑¹,김청수¹·² Introduction: Dendritic cells (DCs) are the most potent antigen-presenting cells and are equipped with the necessary co-stimulatory, adhesion and histocompatibility molecules for initiation of a primary immune response. DC-based vaccination trials in solid cancers have aimed to activate the immune system to recognize and destroy tumor cells. In this study, we investigated the anticancer effect of prostate cancer using anti-cancer immunity cell vaccine based on the next generation dendritic cell immunotherapy. Materials and methods: Dendritic cells were injected once a week for three weeks into a TRAMP-C1 syngeneic mouse model and we investigated for safety, efficacy and induction of prostate cancer antigen-specific immune responses. And we also analyzed proliferation and activation of allogeneic-T cells by therapeutic dendritic cells. The effect of dendritic cells on survival of mice was analyzed by Kaplan-Meier methods. Results: After DC treatment, tumor growth was significantly reduced in stem-DC compared to monocyte-drived dendritic cell (mono-DC) and vehicle group in TRAMP-C1 mouse model. In addition, stem-DC extended survival compared to the Mono-DC and vehicle treated group. To confirm stem-DC/tumor lysate induce more systemic anti-tumor immunity than Mo-DC/tumor lysate, we investigated effector T cells in splenic lymphocytes from mouse model. Finally, the frequency of IFN-γ secreting CD8+ T cells in stem-DC treated group was significantly higher than that in Mo-DC treated group.. Conclusions: Stem-DC, which was developed from hematopoietic stem cells in an optimized manner, proved to be effective and stable as an excellent anti-cancer immunotherapeutic agent for prostate cancer. keywords : Prostate cancer, dendritic cell, Immunotherapy